EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care

Ayesha Appa iD, Gabriela Steiner, Stefan Baral, Elise Riley, Lauren Suchman iD, Kate Roberts iD, Kelly Knight, Meghan Murphy iD, Gabriel Chamie iD, Steve Shoptaw, Phillip O Coffin iD, Monica Gandhi iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Ayesha Appa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Substance-Related Disorders. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIAAA NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stimulants, including cocaine and methamphetamine, are associated with HIV transmission and viremia. Contingency management (CM), which provides financial incentives for nonreactive urine testing, is first-line treatment for stimulant-use disorder (StUD), yet has been minimally studied or integrated into HIV care.

Methods

We conducted a 12-week, single-arm, implementation-effectiveness pilot of weekly CM in a safety-net HIV clinic for persons with HIV (PWH) who have StUD. Participants received escalating incentives for stimulant-negative and/or tenofovir-reactive point-of-care urine assays. Using the RE-AIM framework, we evaluated Reach (demographics, attendance), Effectiveness (stimulant-negative/tenofovir-positive tests, HIV virologic suppression [VS]), and Implementation. We conducted semi-structured, in-depth participant interviews following intervention completion to explore perceived impact and implementation.

Results

From September 2023 to February 2024, we enrolled 31 PWH with StUD: 77% used methamphetamine, 35% cocaine, and 19% fentanyl. Only 17 of 31 (55%) had VS at baseline. Participants attended a mean of 5 of 12 visits (42%). Among PWH who attended postenrollment visits (26/31), 61 of 110 (56%) stimulant tests were negative and 98% (89/91) of tenofovir tests were positive. Postintervention, 88% (23/26) of retained participants achieved VS (P < .01). Qualitative interviews revealed factors enhancing Reach (embedding CM within HIV care), Effectiveness (incentives supporting adherence self-efficacy; program providing structure and motivation), and Implementation (supportive staff relationships, nonjudgmental approach).

Conclusions

Contingency management for stimulant use and/or antiretroviral therapy adherence (using point-of-care tenofovir assays) embedded into HIV care was associated with reduced stimulant use and gains in viral suppression. Scalability of integrating HIV and StUD management using CM merits further evaluation. Clinical Trials Registration. clinicaltrials.gov (NCT06564792).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsSubstance-Related DisordersHumansFemalePilot ProjectsMaleAdultAdherence InterventionsTenofovirMiddle AgedMethamphetamineBehavior TherapyMotivationAnti-HIV AgentsCocaine

Stichwörter der Autor:innen

HIV carecontingency managementimplementation scienceintegrated carestimulant use disorder treatment

Substanzen

TenofovirMethamphetamineAnti-HIV AgentsCocaine

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Francisco, California, USA.
  • Division of Infectious Disease Epidemiology and Center for HIV and Stigma Elimination Strategies, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Social and Behavioral Sciences, University of California, San Francisco, California, USA.
  • Bryn Mawr College Graduate School of Social Work and Social Research, Rosemont, Pennsylvania, USA.
  • Aurrera Health Group, Sacramento, California, USA.
  • Department of Family Medicine, University of California, Los Angeles, California, USA.

ORCID-Profile: Ayesha Appa, Lauren Suchman, Kate Roberts, Meghan Murphy, Gabriel Chamie, Phillip O Coffin, Monica Gandhi

Förderung

  • NIH HHS
  • NIAAA NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Appa, A., Steiner, G., Baral, S., Riley, E., Suchman, L., Roberts, K., Knight, K., Murphy, M., Chamie, G., Shoptaw, S., Coffin, P. O., & Gandhi, M. (2026). Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag006

Vancouver

Appa A, Steiner G, Baral S, Riley E, Suchman L, Roberts K, et al. Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag006

BibTeX
@article{Appa2026,
  author = {Appa, Ayesha and Steiner, Gabriela and Baral, Stefan and Riley, Elise and Suchman, Lauren and Roberts, Kate and Knight, Kelly and Murphy, Meghan and Chamie, Gabriel and Shoptaw, Steve and Coffin, Phillip O and Gandhi, Monica},
  title = {Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag006}
}
Kostenlos starten →